Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 7:03 PM
Ignite Modification Date:
2025-12-24 @ 7:03 PM
NCT ID:
NCT07303257
Brief Summary:
Glaucoma, the leading cause of irreversible blindness, affects more than 60 million people worldwide and 1.3 million in France. Its treatment aims to reduce intraocular pressure, in particular by surgery when eye drops and laser treatment are insufficient.
Conventional filtering techniques and MIGS (Minimally Invasive Glaucoma Surgery), including PreserFlo® MicroShunt, pursue the same objective in terms of blood pressure, but differ in terms of their post-operative profile and tolerability.
Existing studies show similar quality of life scores between filtering and MIGS surgeries. However, no direct comparison has yet been made between trabeculectomy, non-penetrating deep sclerectomy and PreserFlo® at 3 and 6 months, making it pertinent to assess their respective effects on patients' quality of life.
Study:
NCT07303257
Study Brief:
Protocol Section:
NCT07303257